PLOS flags nearly 50 papers by controversial French COVID researcher for ethics concerns

The publisher PLOS is marking nearly 50 articles by Didier Raoult, the French scientist who became controversial for promoting hydroxychloroquine for treating COVID-19, with expressions of concern while it investigates potential research ethics violations in the work. 

PLOS has been looking into more than 100 articles by Raoult, but determined that the issues in 49 of the papers, including reuse of ethics approval reference numbers, warrant expressions of concern while the publisher continues its inquiry. 

In August of 2021, scientific sleuth Elisabeth Bik wrote on her blog about a series of 17 articles from IHU-Méditerranée Infection that described different studies involving homeless people in Marseille over a decade, but all listed the same institutional ethics approval number. One of those papers, “Distinguishing Body Lice from Head Lice by Multiplex Real-Time PCR Analysis of the Phum_PHUM540560 Gene,” about which Bik also posted on PubPeer, was published in PLOS ONE in 2013, and is receiving an expression of concern today. 

Bik and other commenters on PubPeer have identified ethical concerns in many of the other papers PLOS is flagging, including others in large groups of papers with the same ethical approval numbers. Bik has received harassment and legal threats from Raoult.

David Knutson, senior manager of communications for PLOS, sent us this statement: 

PLOS is issuing interim Expressions of Concerns for 49 articles that are linked to researchers affiliated with IHU-Méditerranée Infection (Marseille, France) and/or the Aix-Marseille University, as part of an ongoing case that involves more than 100 articles in total. Many of the papers in this case include controversial scientist Didier Raoult as a co-author. 

Several whistleblowers raised concerns about articles from this institute, including that several ethics approval reference numbers have been reused in many articles. Our investigation, which has been ongoing for more than a year, confirmed ethics approval reuse and also uncovered other issues including: 

• highly prolific authorship (a rate that would equate to nearly 1 article every 3 days for one or more individuals), which calls into question whether PLOS’ authorship criteria have been met 
• undeclared COIs with pharmaceutical companies 

To date, PLOS has completed a detailed initial assessment of 108 articles in total and concluded that 49 warrant an interim Expression of Concern due to the nature of the concerns identified. We’ll be following up with the authors of all articles of concern in accordance with COPE guidance and PLOS policies, but we anticipate it will require at least another year to complete this work.  

Raoult is a coauthor on 48 of the 49 papers in question. He has not responded to our request for comment, nor has IHU-Méditerranée Infection. 

Twenty-eight of the 49 articles, a list of which we’ve made available here, appeared in PLOS ONE between 2010-20, and 19 were published in PLOS Neglected Tropical Diseases between 2011-2. The remaining two were published in PLOS Genetics in 2018 and PLOS Pathogens in 2008. 

The articles all bear the same expression of concern: 

This article [1] has been identified as one of a series of submissions for which we have concerns about the reported research ethics approval information and the article’s adherence to PLOS research ethics policies.

PLOS will be investigating these concerns in accordance with COPE guidance and journal policies. Meanwhile, the PLOS ONE Editors issue this Expression of Concern.

This summer, Raoult retired as director of IHU-Méditerranée Infection, the hospital and research institution in Marseille that he had overseen since 2011, following an inspection by the French National Agency for the Safety of Medicines and Health Products (ANSM) that found “serious shortcomings and non-compliances with the regulations for research involving the human person” at IHU-Méditerranée Infection and another Marseille hospital. 

ANSM imposed sanctions on IHU-Méditerranée Infection, including suspending a research study and placing any new research involving people under supervision, and called for a criminal investigation. Other regulators have also urged Marseille’s prosecutor to investigate “serious malfunctions” at the research institution. 

Pierre-Edouard Fournier, the new director of IHU-Méditerranée Infection, issued a statement on September 7th that said he had “ensured that all clinical trials in progress relating to research involving the human person (RIPH) were suspended pending the regularization of the situation.”

Also in September, the American Society for Microbiology placed expressions of concern on six of Raoult’s papers in two of its journals, citing “a ‘scientific misconduct investigation’ by the University of Aix Marseille,” where the researcher also has an affiliation.

Like Retraction Watch? You can make a tax-deductible contribution to support our work, follow us on Twitter, like us on Facebook, add us to your RSS reader, or subscribe to our daily digest. If you find a retraction that’s not in our database, you can let us know here. For comments or feedback, email us at team@retractionwatch.com.